文献速递疼痛医学神经外科与老年麻醉

左旋紫堇达明通过抑制ASK1-p38 MAPK/NF-κB通路减轻大鼠脊髓小胶质细胞激活和神经病理性疼痛

Levo-corydalmine attenuates microglia activation and neuropathic pain by suppressing ASK1-p38 MAPK/NF-κB signaling pathways in rat spinal cord.
PubMed 文献 · Reg Anesth Pain Med · 2020-01-02

本研究在大鼠慢性坐骨神经压迫损伤(CCI)模型中,发现脊髓ASK1与小胶质细胞标志物Iba1共表达,鞘内注射ASK1抑制剂可抑制脊髓小胶质细胞激活并减轻CCI诱导的神经病理性疼痛。左旋紫堇达明(l-CDL)灌胃给药同样减轻CCI诱导的神经病理性疼痛并抑制脊髓p-ASK1表达,其镇痛效应与抑制ASK1-p38 MAPK/NF-κB轴相关。

要点

  • 脊髓ASK1在小胶质细胞中表达,抑制ASK1可减轻CCI大鼠神经病理性疼痛。
  • l-CDL灌胃减轻CCI诱导的神经病理性疼痛并抑制脊髓小胶质细胞激活。
  • l-CDL镇痛机制与抑制ASK1-p38 MAPK/NF-κB通路及降低TNF-α、IL-1β相关。

核心结论

  • 脊髓小胶质细胞ASK1表达及ASK1-p38 MAPK/NF-κB轴参与CCI诱导的神经病理性疼痛。
  • l-CDL通过抑制ASK1-p38 MAPK/NF-κB轴减轻CCI诱导的神经病理性疼痛。

研究设计与样本

  • 大鼠CCI坐骨神经模型,采用von Frey纤维和Hargreaves法评估痛觉。
  • 采用Western blot和免疫荧光检测信号通路,BV2细胞系用于体外评估。

主要发现

  • 脊髓ASK1与小胶质细胞标志物Iba1共表达。
  • 鞘内注射ASK1抑制剂抑制脊髓小胶质细胞激活并减轻CCI诱导的神经病理性疼痛。
  • ASK1抑制剂降低LPS刺激BV2细胞中p-ASK1、p65、p38 MAPK及TNF-α、IL-1β mRNA水平。
  • l-CDL灌胃减轻CCI诱导的神经病理性疼痛并抑制脊髓p-ASK1表达,体内外抑制小胶质细胞激活。
  • l-CDL抑制NF-κB核转位及p-p65、TNF-α、IL-1β上调,并降低p-PKCγ、JNK、ERK水平。

临床怎么用

  • l-CDL及ASK1抑制剂在CCI大鼠中显示镇痛作用,提示ASK1-p38 MAPK/NF-κB轴为神经病理性疼痛潜在干预靶点。
  • 目前证据限于大鼠模型和BV2细胞,尚不能直接推导临床用药方案。

局限性

  • 研究仅在大鼠CCI模型和BV2细胞系中进行,未提供人体数据。
  • 原文未报告样本量、具体剂量及统计学P值等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Neuropathic pain is partially refractory to currently available treatments. Although some studies have reported that apoptosis signal-regulating kinase 1 (ASK1) may inhibit chronic pain, the mechanisms underlying this process have not been fully elucidated. METHODS: Chronic constriction injury (CCI) of the rat sciatic nerve was used to establish a neuropathic pain model. Nociception was assessed using von Frey hair and Hargreaves' methods. Western blot and immunofluorescence were used to detect the cell signaling pathway. BV2 cell line was cultured for in vitro evaluation. RESULTS: Our results indicated that spinal ASK1 was co-expressed with the microglia marker ionized calcium binding adaptor 1. Additionally, intrathecal administration of ASK1 inhibitor suppressed the activation of spinal microglia and attenuated CCI-induced neuropathic pain. The ASK1 inhibitor also decreased the levels of phosphorylated ASK1 (p-ASK1), p65, p38 mitogen-activated protein kinase (MAPK) and tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) messenger RNA in lipopolysaccharide-stimulated BV2 microglia cells. Intragastric administration of levo-corydalmine (l-CDL) significantly attenuated CCI-induced neuropathic pain and inhibited the expression of p-ASK1 in the spinal cord. l-CDL conspicuously suppressed the activation of spinal microglia in vitro and in vivo. Translocation of nuclearfactor-kappa B (NF-κB) and upregulation of p-p65, TNF-α, IL-1β were inhibited by l-CDL. Further, the analgesic effects of l-CDL were associated with reduced levels of phosphorylated protein kinase C (PKC γ), c-JunNH2-terminal kinase, and extracellular signal-regulated kinase. CONCLUSIONS: This study showed that the expression of ASK1 in spinal microglia and ASK1 inhibitor suppressed microglia activation via suppression of p38 MAPK/NF-κB, which ultimately attenuated CCI-induced neuropathic pain. l-CDL also inhibited the ASK1-P38 MAPK/NF-κB axis to attenuate CCI-induced neuropathic pain.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Dai WL, Bao YN, Fan JF, et al. Levo-corydalmine attenuates microglia activation and neuropathic pain by suppressing ASK1-p38 MAPK/NF-κB signaling pathways in rat spinal cord. Reg Anesth Pain Med. 2020. PMID: 31898581. doi:10.1136/rapm-2019-100875

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。